Navigation Links
caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
Date:6/29/2010

BERLIN and BURLINGTON, Mass., June 29 /PRNewswire/ -- caprotec bioanalytics GmbH announced today that it has successfully completed a research collaboration with F. Hoffmann-La Roche, Basel, Switzerland. Under the collaboration research agreement, caprotec used its proprietary CCMS (Capture Compound Mass Spectrometry) technology to analyze the binding characteristics and interaction of one undisclosed drug candidate with its human target proteins.

To identify selectively interacting proteins of a drug molecule, it is coupled to caprotec's Capture Compound™ scaffold and incubated with human cell lysates, subcellular fractions or whole cells. Interacting proteins are then isolated and identified via Liquid Chromatography-Mass Spectrometry/Mass.  Among the protein targets that demonstrated specific binding of Roche's drug molecule were some which show activity in pathways commensurate with the phenotypic profile of the candidate drug molecule.

"The results of this drug-protein profiling study confirm again the capability of our CCMS technology to directly isolate a functional subset of proteins from a complex biological sample for the identification of previously unknown interactions with small molecules," said Dr. Hubert Koster, CEO of caprotec. "This fills a crucial technological gap in the arsenal of methods available for optimizing drug structures and to select the most promising candidate drugs before entering the clinical trial process as well as drug safety assessment."

"This project demonstrated that the CCMS technology is robust and yields high quality results that are complementary to our internal research efforts. We are very pleased with the outcome of this collaboration", stated Dr. Stephan Rover, Scientific Expert for Discovery Chemistry at Roche.

About caprotec bioanalytics GmbH

caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples in solution. After isolation, the captured proteins including membrane proteins are identified by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of protein biomarkers. The technology is protected by a broad patent portfolio. The company is supported by an international scientific advisory board including one Nobel Laureate.

www.caprotec.com


'/>"/>
SOURCE caprotec bioanalytics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
2. Serono Symposia International Foundation in Collaboration With ESHRE Announces Public Competition in Reproductive Medicine
3. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
4. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
5. Breckenridge Announces Approval of Anastrozole Tablets
6. American Medical Systems Announces FDA Clearance for MiniArc(R) Precise Single-Incision Sling
7. Recondo Technology Announces Integration Initiative for US Hospital Systems
8. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
9. Solta Medical Announces Thermage CPT™ and Fraxel re:store® Dual Systems Receive Health Canada Approval
10. Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments
11. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 ... specialty clinical-stage pharmaceutical company specializing in the development of ... public offering in the United States ... each ADS representing 40 ordinary shares of the ... In addition, Therapix has granted the underwriters a ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... health plans work, the Self-Funding Success website has recently developed and published an ... Health Plans ” was created based on common inquiries the site’s team of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and ... thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. The ... Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud ...
Breaking Medicine News(10 mins):